Project 2. Enhancing Glioma Immunotherapy with Temodar-lnduced Lymphopenia and a Multivalent Vaccine. John H. Sampson, M.D., Ph.D., M.H.Sc., Project Leader Despite the demonstrated capacity for the immune system to eliminate tumor cells with exquisite precision in preclinical models, active immunotherapy against human neoplasms has met with relatively few clinical successes. However, our vaccines targeting the tumor-specific epidermal growth factor receptor mutation, EGFRvlll, when given during recovery from temozolomide (TMZ)-induced lymphopenia have produced strong humoral and CD8+ and CD4+ T-cell responses that are accompanied by radiographic responses in all patients with residual disease and a median survival that exceeds 32 months. Vaccination eliminates EGFRvlll-expressing tumor cells. This illustrates the effectiveness of immunologic targeting, but EGFRvlll-negative tumor recurrence in this setting underscores the need to develop an effective therapy that addresses the heterogeneity of antigen expression in GBM. We believe that the potent and specific immune responses generated against EGFRvlll in our studies were potentiated by TMZ. The homeostatic proliferation that occurs after TMZ-induced lymphodepletion reduces the threshold for lymphocyte activation and proliferation. Our murine models have demonstrated that vaccine responses can be dramatically enhanced in TMZ-pretreated mice in a dose-dependent manner and dose-intensified TMZ regimens in patients with GBM have resulted in dramatically enhanced cellular and humoral responses to vaccination. These results have highlighted the potential to leverage the recovery from TMZ-induced lymphopenia as a potentially novel mechanism to enhance active immunotherapy against GBM. In an attempt to broaden the response seen when targeting EGFRvlll in this context, we propose to evaluate total tumor-RNA loaded dendritic cell vaccines. Mechanistic understanding of the effects of TMZ on the induction and maintenance of antitumor immunity will be explored in relevant murine astrocytoma models in order to rationally develop enhanced immunotherapeutic treatments for patients with GBM.

Public Health Relevance

Treatment for malignant primary brain tumors is ineffective and represents the most expensive medical therapy per quality-adjusted life-year saved currently provided in the USA. The only major side effect of temozolomide, the only successful chemotherapeutic for this disease, is bone marrow suppression. We believe this suppression may dramatically enhance antitumor immunity and will investigate this possibility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS020023-29
Application #
8376991
Study Section
Special Emphasis Panel (ZNS1-SRB-G)
Project Start
Project End
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
29
Fiscal Year
2012
Total Cost
$214,513
Indirect Cost
$15,139
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Slastnikova, Tatiana A; Rosenkranz, Andrey A; Zalutsky, Michael R et al. (2015) Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des 21:1227-38
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Hodges, Tiffany R; Choi, Bryan D; Bigner, Darell D et al. (2013) Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. J Neurosurg 118:1176-80

Showing the most recent 10 out of 141 publications